Pharmacoscintigraphy: A blazing trail for the evaluation of new drugs and delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 26, Issue 4, 2009, Pages 373-426

  Jain, Sanyog ^a,b   Dani, Prateek ^a   Sharma, Rakesh Kumar ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Diagnostic imaging; Gamma scintigraphy; Noninvasive imaging; Novel drug delivery systems; Pharmacoscintigraphy; Site targeting

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BARIUM 138; BENZIMIDAZOLE DERIVATIVE; CHOLECYSTOKININ RECEPTOR; DICLOFENAC; DIDANOSINE; DILTIAZEM; DOPAMINE TRANSPORTER; ERBIUM 170; FUROSEMIDE; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 131; KRYPTON 81M; LIPOSOME; MICROSPHERE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NANOPARTICLE; NAPROXEN; OLANZAPINE; RADIOISOTOPE; SAMARIUM 152; SEROTONIN TRANSPORTER; TECHNETIUM 99M; THALLIUM 201; THEOPHYLLINE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

BIOEQUIVALENCE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG MONITORING; DRUG RELEASE; DRUG RESEARCH; DRUG TARGETING; DRUG UPTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAMMA SCINTIGRAPHY; HUMAN; ISOTOPE LABELING; LYMPHOCYTE HOMING; NEUTRON ACTIVATION ANALYSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACOSCINTIGRAPHY; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DECAY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED DRUG RELEASE;

EID: 72449201995     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i4.20     Document Type: Review

References (147)

1. Singh AK, Bharadwaj N, Bhatnagar A. Pharmacoscintigraphy: An unexplored modality in India. Ind J Pharm Sci. 2004;66(1):18-25.
2. Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des. 2004;10(24):2907-2921
3. Belcher E, Vetter H. Radioisotope techniques. In: Butterworth L, Freeman LM, Johnson PM, editors. Clinical scintillation imaging. 2nd ed. New York (NY): Grune and Stratton; 1971.
4. Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med. 1992;19:971-986
5. Meseguer G, Gurny R, Buri P. In vivo evaluation of dosage forms: application of gamma scintigraphy to nonenteral routes of administration. J Drug Target. 1994;2:269-288
6. Wong D, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2009;34:187-203.
7. Buchanan L, Jurek P, Redshaw R. Nuclear imaging drug development tools: PET and SPECT help enhance the quality of a product and prevent late-stage failure. Gen Eng Biotech. 2007;27:1-2.
8. 8. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an evolving technology in pharmaceutical formulation development-Part 2. Pharm Sci Tech. 1998; 1(4): 160-165 (Pubitemid 28343471)
9. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an evolving technology in pharmaceutical formulation development-Part 1. Pharm Sci Tech. 1998; 1(3): 100-108
10. Amighi K, Pilcer G, Goole J, Gansbeke BV, Blocklet D, Knoop C, Vanderbist F. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm. 2008;68:413-421
11. Al-Ghananeem AM, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA. Gamma scintigraphy for testing bioequivalence: A case study on two cromolyn sodium nasal spray preparations. Int J Pharm. 2008;357(1-2):70-76
12. 12. Bennink R, van Montfrans C, de Jonge W, de Bruin K, van Deventer S, Velde A. Imaging of intestinal lymphocyte homing by means of pinhole SPECT in a TNBS colitis mouse model. Nucl Med Biol. 2004;31(1):93-101. (Pubitemid 38115129)
13. 13. Wang R, Zhang C, Zhu S, Zhu M. A comparative study of samarium153-Ethylenediaminetetramethylene phosphonic acid with Pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract. 2003;12(2):97-101. (Pubitemid 36356886)
14. Garg M, Garg B, Jain S, Mishra P, Sharma RK, Mishra AK, Dutta T, Jain NK. Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur J Pharm Sci. 2008;33 271-281
15. Pathak A, Kumar P, Chuttani K, Jain S, Mishra A, Vyas S, Gupta K. Gene expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate PEI nanoconstructs mediated tumor gene therapy. ACS Nano. 2009;3(6): 1493-1505
16. Reddy L, Sharma R, Murthy R. Enhanced delivery of etoposide to Dalton's lymphoma in mice through polysorbate 20 micelles. Acta Pharm. 2006;56:143-155
17. Perkins AC. instrumentation, imaging, data analysis and display. London (UK): Taylor & Francis; 1999.
18. Wilson CG, Perkins AC. Gamma scintigraphy and the study of drug deposition. 1st ed. London (UK): Academic Press; 1992.
19. 19. Parr A, Beihn RM, Jay M. Radiolabeling of an enteric coated tablet by (n, γ) radioactivation of Erbium-170 for scintigraphic imaging. Int J Pharm. 1986;32:251-256 (Pubitemid 16015307)
20. Parr A, Jay M. Radiolabeling of intact dosage forms by neutron activation: effects on in vitro performance. Pharm Res. 1987;4(6): 524-526
21. Parr A, Jay M, Digenis GA, Beihn RM. Radiolabeling of intact tablets by neutron activation for in vivo scintigraphic studies. J Pharm Sci 1985;74(5):590-591
22. 22. Parr AF, Beihn RM, Franz RM, Szpunar GJ, Jay M. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of Erbium-171- labeled sustained-release tablets. Pharm Res. 1987;4(6):486-489 (Pubitemid 18035242)
23. 23. Ahrabi SF, Sande SA, Waaler T, Graffner C. Effects of thermal neutron irradiation on some potential excipients for colonic delivery systems. Drug Dev Ind Pharm Res. 1999;25(4):453-462 (Pubitemid 29159424)
24. 24. Ahrabi SF, Sande SA, Waaler T, Graffner C. Influence of neutron activation factors on the physico-chemical properties of suppositories and their excipients. Eur J Pharm Sci. 1999;8:193-201. (Pubitemid 29324647)
25. Watts PJ, Atkin BP, Wilson CG, Davies MC, Melia CD. Radiolabeling of polymer microspheres for scintigraphic investigations by neutron activation. 1. Incorporation of samarium oxide and its effects on the properties of Eudragit RS: sulfasalazine microspheres. Int J Pharm. 1991(76):55-59
26. Digenis GA, Parr AF, Jay M. Neutron activation methods for evaluation of pharmaceutical dosage forms. 1st ed. Chichester (UK): Ellis Horwood; 1989.
27. Reichert DE, Lewis JS, Anderson CJ. Metal complexes as diagnostic tools. Coord Chem Rev. 1999;184(1):3-66.
28. 28. Maitra A, Banerjee T, Singh A, Sharma R. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Int J Pharm. 2005;289(1-2): 189-195 (Pubitemid 40093553)
29. Hargreaves R. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther. 2008;83(2):349-353
30. Pauwels E, Bergstrom K, Mariáni G, Kairemo K. Microdosing, imaging biomarkers and SPECT: a multi-sided tripod to accelerate drug development. Curr Pharm Des. 2009;15(9):928-934
31. 31. Chalon S, Guilloteau D. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des. 2005;11(25):3237-3245 (Pubitemid 41300774)
32. Beer H, Rossetti I, Frey L, Hasler P, Schubiger P. 123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Nucl Med Biol. 1995 22(7):929-936
33. Stone J. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des. 2009;15(22):2594-2602
34. 34. Tiwari AK, Mishra AK, Bajpai A, Mishra P, Singh S, Sinha D, Singh VK. Synthesis and evaluation of novel benzimidazole derivative [Bz-Im] and its radio/biological studies. Bioorg Med Chem Lett. 2007;17(10):2749-2755 (Pubitemid 46636256)
35. Chuttani K, Mishra P, Chopra M, Panwar P, Sharma R, Mishra A. Radiolabeling and biological evaluation of a non-peptidic compound from Terminalia chebula (Harar) for CCK expressing tumours. Ind J Nue Med. 2003; 18(1-2): 19-24.
36. Wang Y, Yan S. Biomedical imaging in the safety evaluation of new drugs. Lab Anim. 2008;42(4):433-441
37. 37. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HNE. Invitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations: A pharmacoscintigraphic study in the beagle dog. Eur J Pharm Biopharm. 2007;67:515-523 (Pubitemid 47211908)
38. Christrup LL, Davis SS, Frier M, Melia CD, Rasmussen SN, Washington N, Wilding IR, Andersen C. Deposition of a model substance, 99mTc E-HIDA, in the oral cavity after administration of lozenges, chewing gum and sublingual tablets. Int J Pharm. 1990;66:169-174
39. Davis S, Kennerley J, Taylor M, Hardy J, Wilson C. Scintigraphic studies on the in vivo dissolution of a buccal tablet. Int Congr Symp; 1983. p. 29-37.
40. Wilson CG, Washington N, Peach J, Murray GR, Kennerley J. The behavior of a fast-dissolving dosage form (Expidet) followed by γ-scintigraphy. Int J Pharm. 1987;40:119-123
41. Watts PJ, Wilson CG, Davies MC, Melia CD. Radiolabeling of polymer microspheres for scintigraphic investigations by neutron activation. 2. Effects of irradiation on the properties of Eudragit RS-sulfasalazine microspheres. Int J Pharm. 1993;98(1-3):63-73.
42. Watts PJ, Wilson CG, Davies MC, Melia CD. Radiolabeling of polymer microspheres for scintigraphic investigations by neutron activation. 3. Changes in the physical properties of Eudragit RS-sulfapyridine microspheres from incorporating samarium oxide. Int J Pharm. 1993;98(1-3):75-82.
43. Fairweather-Tait SJ, Minihane A, Eagles J, Owen L, Crews HM. Rare earth elements as nonabsorbable fecal markers in studies of iron absorption. Am J Clin Nutr 1997;65:970-976 (Pubitemid 27152613)
44. Nick C. Formulations on trial. Good Clin Pract. 1996;30:20-26
45. 45. Newman S, Hirst P, Wilding I. New developments in radionuclide imaging for assessing drug delivery in man. Eur J Pharm Sci. 2003;18: 19-22. (Pubitemid 36120551)
46. Wilding I, Davis SS, Sparrow RA, Ziemniak JA, Heald DL. Pharmacoscintigraphic evaluation of a modified release (Geomatrix®diltiazem formulation. J Control Release. 1995;33:89-97.
47. Kenyon C, Hooper G, Tierney D, Butler J, Devane J, Wilding I. The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. J Control Release. 1995 34:31-36
48. 48. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gammascintigraphy. J Control Release. 1999;58:195-205. (Pubitemid 29112890)
49. 49. Yuen K-H, Billa N, Khader MAA, Omar A. Gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. Int J Pharm. 2000;201(1): 109-120 (Pubitemid 30364974)
50. 50. Clear NJ, Milton A, Humphrey M, Henry BT, Wulff M, Nichols DJ, Anziano RJ, Wilding I. Evaluation of the Intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon. Eur J Pharm Sci. 2001;13(4):375-384 (Pubitemid 32618646)
51. 51. Damle B, Ismat U, Walter D, Gary W, Knupp C. Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers. Br J Clin Pharmacol. 2002;54:255-261 (Pubitemid 35056569)
52. 52. Stevens HNE, Wilson CG, Welling PG, Bakhshaee M, Binns JS, Perkins AC, Frier M, Blackshaw EP, Frame MW, Nichols DJ, Humphrey MJ, Wicks SR. Evaluation of Pulsincap™ to provide regional delivery of dofetilide to the human GI tract. Int J Pharm. 2002;236(1-2):27-34. (Pubitemid 34219370)
53. 53. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H, Fujibayashi Y. Pharmacoscintigraphic evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans. J Control Release. 2004;98:75-85. (Pubitemid 38881609)
54. 54. Ofori-Kwakye K, Fell JT, Sharma HL, Smith. A-M. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. Int J Pharm. 2004;270 307-313 (Pubitemid 38077110)
55. Ma N, Xu L, Wang Q, Zhang X, Zhang W, Li Y, Jin L, Li S. Development and evaluation of new sustained-release floating microspheres. Int J Pharm. 2008;358:82-90.
56. 56. Ponchel G, Irache J. Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract. Adv Drug Del Rev. 1998;34:191-219. (Pubitemid 28535112)
57. Lenaerts V, Gurny R. Gastrointestinal tract: Physiological variables affecting the performance of oral sustained release dosage forms. In Lenaerts V, Gurny R, editors. Bioadhesive drug delivery systems. Boca Raton (FL): CRC Press; 1990.
58. Urguhart J, Theeuwes F (inventors). Drug delivery system comprising a reservoir containing a plurality of tiny pills. U.S. Patent 4434153. 1994.
59. Fix J, Cargill R, Engle K. Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers. Pharm Res. 1993;10:1087-1089
60. 60. Deshpande A, Shah N, Rhodes C, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997;14:815-819 (Pubitemid 27281680)
61. 61. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage-studies on the absorption of nitrofurantion. Int J Pharm. 1989;56:111-116 (Pubitemid 19283754)
62. 62. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm. 1984;10:527-539 (Pubitemid 14122735)
63. Timmermans J, Gansbeke V, Moes A. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Proceedings of the 5th International Conference on Pharmacy Technology. Paris, France: APGI; 1989. p. 42-51.
64. Shimpi S, Chauhan B, Mahadik K, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech. 2004;5(3):51-56
65. 65. Burke M, Staton S, Vickers A, Peters E, Coffin M. A novel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment. Pharm Res. 2007;24(4):695-704. (Pubitemid 46411959)
66. Yao H, Xu L, Han F, Che X, Dong Y, Wei M, Guan J, Shi X, Li S. A novel riboflavin gastro-mucoadhesive delivery system based on ionexchange fiber. Int J Pharm. 2008;364:21-26
67. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, Baboota S. Formulation and development of hydrodynamically balanced system for metformin: In vitro and in vivo evaluation. Eur J Pharm Biopharm. 2007;67:196-201.
68. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK. Formulation and development of floating capsules of celecoxib: in vitro and in vivo evaluation. AAPS PharmSciTech. 2007;8(4):312-319
69. 69. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gammascintigraphy. J Control Release. 1999;58(2): 195-205. (Pubitemid 29112890)
70. Watts PJ, Barrow L, Steed KP, Wilson CG, Spiller RC, Melia CD, Davies MC. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int J Pharm. 1992;87(1-3):215-221
71. 71. Jarnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs. 1989;37:73-86. (Pubitemid 19086733)
72. Dew MJ, Ryder RE, Evans N, Evans BK, Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Brit J Clin Pharmcol. 1983;16:185-187
73. Davis SS, Hardy JG, Wilson CG, Feely LC, Palm KJ. Gastrointestinal transit of a controlled release naproxen tablet formulation. Int J Pharm. 1986;32:85-90.
74. 74. Buszello K, Schnier C, Müller BW. Radiolabeling of parenteral O/W emulsions by means of neutron activation. Eur J Pharm Biopharm. 1999;47:247-253 (Pubitemid 29257883)
75. Awang MB, Hardy JG, Davis SS, Wilding IR, Parry SJ. Radiolabeling of pharmaceutical dosage forms by neutron activation of samarium-152. J Labelled Comp Radiopharm. 1993;33:941-948
76. Adkin DA, Davis SS, Sparrow RA, Wilding IR. Colonic transit of different sized tablets in healthy subjects. J Control Release. 1993;23(2): 147-156
77. Olsson B, Wagner ZG, Mansson P, Ragnarsson G. A gamma scintigraphic study of the absorption of morphine from controlled-release tablets. Int J Pharm. 1995;119(2):223-229
78. 78. Abrahamsson B, Alpsten M, Jonsson UE, Lundberg PJ, Sandberg A, Sundgren M, Svenheden A, Tolli J. Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon. Int J Pharm. 1996;140(2):229-235 (Pubitemid 26292769)
79. 79. Satyanarayan S, Krishnaiah YSR, Rama Prasad YV, Narasimha Rao S. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release. 1998;55:245-252 (Pubitemid 28477615)
80. 80. Krishnaiah YSR, Satyanarayana S, Rama Prasad YV, Narasimha Rao S. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm. 1998; 171(2): 137-146 (Pubitemid 29023106)
81. Fell JT, Macleod GS, Collett JH, Sharma HL, Smith A-M. Selective drug delivery to the colon using pectin:chitosan:hydroxypropyl methylcellulose film coated tablets. Int J Pharm. 1999;187(2):251-257
82. 82. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit H-U, Schminke C, Beckert T, Cade D. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002;231:83-95. (Pubitemid 33086822)
83. 83. Charles O, Paul S, Joanne B, Albert D, Baolian L, Wilding I. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm. 2003;257(1-2):297-299 (Pubitemid 36507055)
84. 84. Zhang R, Xing L, Dawei C, Liping X. Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Control Release. 2003;93(3):293-300. (Pubitemid 37485951)
85. 85. Goto T, Tanida N, Yoshinaga T, Sato S, Ball DJ, Wilding IR, Kobayashi E, Fujimura A. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans. J Control Release. 2004;97(1):31-42. (Pubitemid 38624507)
86. 86. Basit A, Podczeck F, Michael N, Waddington W, Ell P, Lacey L. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur J Pharm Sci. 2004;21(2-3): 179-189 (Pubitemid 38156155)
87. Sinha VR, Mittal BR, Kumria R. In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery. Int J Pharm. 2005;289(1-2):79-85.
88. 88. Marvola T, Marvola J, Kanerva H, Ahonen A, Lindevall K, Marvola M. Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon. Int J Pharm. 2008;349(1-2):24-29 (Pubitemid 350299683)
89. Anande NM, Jain SK, Jain NK. Con-A conjugated mucoadhesive microspheres for the colonic delivery of diloxanide furoate. Int J Pharm. 2008;359(1-2): 182-189
90. Hodges LA, Connolly SM, Band J, O'Mahony B, Ugurlu T, Turkoglu M, Wilson CG, Stevens HNE. Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers. Int J Pharm. 2008;370(1-2): 144-150
91. Gupta H, Aqil M, Khar R, Ali A, Bhatnagar A, Mittal G, Jain S. Development and characterization of 99mTc-timolol maleate for evaluating efficacy of in situ ocular drug delivery system. AAPS PharmSciTech. 2009;10(2):540-546
92. De Boer A, Moolenaar F, de Leede L, Breimer D. Rectal Drug Administration-Clinical Pharmacokinetic Consideration. Clin Pharmacokin. 1982;7:285-311.
93. 93. Hardy JG, Feely L, Wood E, Davis SS. The application of gamma scintigraphy for the evaluation of the relative spreading of suppository bases in rectal hard gelatin capsules. Int J Pharm. 1987;38:103-108 (Pubitemid 17148760)
94. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm. 1985;25(2):191-197
95. Wolff RK, Niven RW. Generation of aerosolized drugs. J Aerosol Med. 1994;7:89-106.
96. 96. Newman S, Wilding I. Gamma scintigraphy: an in vivo technique for assessing the equivalence of inhaled products. Int J Pharm. 1998(170):1-9. (Pubitemid 28473241)
97. Zanen P, Lammers J. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol. 1995;48:179-184
98. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst. 1993;10:65-109.
99. 99. Perring S, Summers Q, Fleming JS, Nassim MA, Holgate ST. A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol. 1994;67:46-53. (Pubitemid 24026446)
100. 100. Borgstrom L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 1990;7:1069-1070 (Pubitemid 20366736)
101. Singh D, Parmar J, Hegde D, Menon M, Soni P, Samad A, Gaikwad R. Poloxamer coated fluticasone propionate microparticles for pulmonary delivery; In vivo lung deposition and efficacy studies. Indian J Pharm Sci. 2007;69:714-715
102. Parmar J, Singh D, Hegde D, Menon M, Soni P, Samad A, Gaikwad R. Sustained release budesonide liposomes: Lung deposition and efficacy evaluation. Ind J Pharm Sci. 2007;69:716-717
103. 103. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in-situ gel system. Drug Deliv. 2007;14(8): 507-515 (Pubitemid 350135850)
104. 104. Nagarsenker M, Londhe V, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190:63-71. (Pubitemid 29467473)
105. 105. Snibson G, Greaves J, Soper N, Prydal J, Wilson C, Bron A. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye. 1990;4(4):594-602. (Pubitemid 20376820)
106. 106. Greaves J, Wilson C, Rozier A, Grove J, Plazonnet B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res. 1990;9(5):415-420 (Pubitemid 20203500)
107. Fitzgerald P, Wilson C, Greaves J, Frier M, Hollingsbee D, Gilbert D, Richardson M. Scintigraphic assessment of the precorneal residence of a new ophthalmic delivery system (NODS) in man. Int J Pharm. 1992;83(1-3):177-185
108. Greaves J, Wilson C, Birmingham A, Richardson M, Bentley P. Scintigraphic studies on the corneal residence of a New Ophthalmic Delivery System (NODS): rate of clearance of a soluble marker in relation to duration of pharmacological action of pilocarpine. Br J Clin Pharmacol. 1992;33(6):603-609
109. 109. Greaves J, Wilson C, Birmingham A. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. Br J Clin Pharmac. 1993;35:188-192 (Pubitemid 23055322)
110. 110. Meseguer G, Gurny R, Buri P, Rozier A, Plazonnet B. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. Int J Pharm. 1993;95(1-3):229-234 (Pubitemid 23203156)
111. 111. Meseguer G, Buri P, Planzonnet B, Rozier A, Gurny R. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther. 1996;12(4):481-488 (Pubitemid 26405752)
112. 112. Colao A, Lastoria S, Ferone D, Pivonello R, Macchia P, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G. Orbital scintigraphy with [111In-Diethylenetriamine pentaacetic acid-D-Phel]-Octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 1998;83(11):3790-3794 (Pubitemid 28513552)
113. 113. Wei G, Xu H, Ding P, Li S, Zheng J. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release. 2002;83 65-74. (Pubitemid 35239815)
114. 114. Senthilkumari S, Velpandian T, Biswas NK, Sonali N, Ghose S. Evaluation of the impact of P-glycoprotein (P-gp) drug efflux transporter blocked on the systemic and ocular disposition of P-gp substrate. J Ocul Pharmacol Ther. 2007;24:290-300. (Pubitemid 351733222)
115. Senthilkumari S, Velpandian T, Biswas NK, Saxena R, Ghose S. Evaluation of the modulation of P-glycoprotein (P-gp) on the intra ocular disposition of its substrate in rabbits. Curr Eye Res. 2008;33:333-343
116. Senthilkumari S, Velpandian T, Biswas N, Bhatnagar A, Mittal G, Ghose S. Evidencing the modulation of P-glycoprotein at blood-ocular barriers using gamma scintigraphy. Curr Eye Res. 2009;34(1):73-77
117. 117. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthya RSR. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release. 2005;105:185-198 (Pubitemid 40941985)
118. 118. Maitra A, Banerjee T, Mitra S, Singh AK, Sharma R. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm. 2002;243:93-105. (Pubitemid 34907960)
119. Subramanian N, Arulsudar N, Chuttani K, Mishra P, Sharma RK, Murthy RSR. Radiolabeling, biodistribution and tumor imaging of stealth liposomes containing methotrexate. J Alasbimn. 2003;6(22):AJ22-6.
120. Murthy RSR, Arulsudar N, Subramanian N, Mishra P, Chuttani K, Sharma RK. Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich Ascites Tumor-bearing mice. AAPS J. 2008;6(1):45-56.
121. 121. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RSR. Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation. J Drug Target. 2004; 12(9-10):549-557 (Pubitemid 40100702)
122. 122. Reddy L, Sharma R, Murthy R. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's Lymphoma tumour. J Drug Target. 2004;12(7):443-451 (Pubitemid 39562428)
123. 123. Vyas T, Babbar AK, Sharma RK, Mishra A. Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target. 2005;13(5):317-324 (Pubitemid 41283165)
124. Soni S, Babbar AK, Sharma RK, Maitra A. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J Drug Target. 2006;14(2):87-95.
125. Misra A, Vyas T, Babbar A, Sharma R, Singh S. Preliminary braintargeting studies on iIntranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech. 2006;7(1):E49-57.
126. Geze A, Tieu CL, Choisnard L, Mathieu J, Marti-Batlle D, Riou L, Putaux J, Wouessidjewe D. Biodistribution of intravenously administered amphiphilic beta-cyclodextrin nanospheres. Int J Pharm. 2007;344:135-142
127. Agashe HB, Babbar AK, Jain S, Sharma RK, Mishra AK, Asthana A, Garg M, Dutta T, Jain NK. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Nanomedicine. 2007;3:120-127
128. Agrawal G, Yadav A, Mishra P, Mishra A, Mishra P, Jain S. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine. 2007;3: 246-257
129. Mata JE, Dyal LA, Slauson ME, Summerton JE, Loehr C, Tyson AR, Rodriguez-Proteau R, Gustafson SB. Tumor imaging using technetium99m bound to pH-sensitive peptides. Nanomedicine. 2007;3:297-305.
130. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285-291
131. Yadav MR, Pawar VP, Marvaniya SM, Halen PK, Giridhar R, Mishra AK. Site specific chemical delivery of NSAIDs to inflamed joints: Synthesis, biological activity and c-imaging studies of quaternary ammonium salts of tropinol esters of some NSAIDs or their active metabolites. Bioorg Med Chem. 2008;16(21):9443-9449
132. Misra A, Jogani V, Shah P, Mishra P, Mishra AK. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008;22(2): 116-124
133. Ghandehari H, Borgman MP, Coleman T, Kolhatkar RB, Geyser-Stoops S, Line BR. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A"-DTPA) conjugates show increased kidney accumulation. J Control Release. 2008;132:193-199
134. Soni S, Babbar A, Sharma R, Banerjee T, Maitra A. Pharmacoscintigraphic evaluation of polysorbate80-coated chitosan nanoparticles for brain targeting. Am J Drug Deliv. 2005;3(3):205-212
135. Panwar P, Shrivastava V, Tandon V, Mishra P, Chuttani K, Sharma RK, Chandra R, AK M. 99mTc-Tetraethylenepentamine-Folate-a new 99mTc-based folate derivative for the detection of folate receptor positive tumors: synthesis and biological evaluation. Cancer Biol Ther. 2004;3(10):995-1001.
136. Pathak A, Patnaik S, Swami A, Chutani K, Jain S, Mishra A, Vyas S, Gupta K. Efficient tumor targeting by polysaccharide decked polyethylenimine based nanocomposites. J Biomed Nanotech. 2009;5(3):264-277
137. Shukla G, Tiwari A, Sinha D, Srivastava R, Cahndra H, Mishra A. Synthesis and assessment of 99mTc chelate-conjugated alendronate for development of specific radiopharmaceuticals. Cancer Biother Radiopharm. 2009;24(2):209-214
138. 138. Arulsudar N, Subramanian N, Mishra P, Sharma RK, Murthy RSR. Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target. 2003; 11(3): 187-196 (Pubitemid 37236332)
139. Datta A, Panwar P, Chuttani K, Mishra A. Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases. Cancer Biother Radiopharm. 2009;24(1): 123-128
140. 140. Samad A, Sultana Y, Khar R, Aqil M, Kalam MA, Chuttani K, Mishra AK. Radiolabeling and evaluation of alginate blend-isoniazid microspheres by 99mTc for the treatment of tuberculosis in rabbit model. J Drug Target. 2008;16(6):509-515 (Pubitemid 352015820)
141. 141. Sharma R, Tewari K, Bhatnagar A, Mondal A, Mishra A, Singh A, Chopra M, Rawat H, Kashyap R, Tripathi R. Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med. 2007;32(5):367-370 (Pubitemid 46659170)
142. 142. Rothkamm K, Lobrich M. Misrejoining of DNA double-strand breaks in primary and transformed human and rodent cells: a comparison between the HPRT region and other genomic locations. Mutat Res. 1999;433:193-205. (Pubitemid 29206688)
143. Zolle I. Technetium-99m pharmaceuticals-preparation and quality control in nuclear medicine. Berlin (Germany): Springer; 2007.
144. International Commission on Radiological Protection. ICRP publication 62: radiological protection in biomedical research. Ann ICRP. 1993;22(3).
145. International Commission on Radiological Protection. ICRP publication 103: recommendations of the ICRP. Ann ICRP. 2008;37(2-4).
146. U.S. Food and Drug Administration, Title 21, Code of Federal Registrations, Part 361. Washington (DC): Office of the Federal Register, National Archives and Records Administration; 2009.
147. Verbruggen A, Coenen HH, Deverre J-R, Guilloteau D, Langstrom B, Salvadoři PA, Halldin C. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging. 2008;35(11):2144-2151